SEC filing · 8-K

AbbVie Inc.: Quarterly results

AbbVie updated its 2026 earnings guidance to reflect third-quarter acquired IPR&D and milestones expense.

Filed October 5, 2026

Negative for the company

What happened

The company expects third-quarter 2026 GAAP and adjusted non-GAAP earnings to include pre-tax acquired IPR&D and milestones expense of $216 million.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to AbbVie Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.